1.67  -0.1 (-5.65%)		03-03 16:00
Open: 1.74 High: 1.74 Volume: 43,144		Pre. Close: 1.77 Low: 1.5901 Market Cap: 18(M)

Short term
Mid term
Targets	6-month :	3.62	1-year :	4.76
Resists	First :	3.1	Second :	4.07
Pivot price	1.74
Supports	First :	1.53	Second :	1.27
MAs	MA(5) :	1.75	MA(20) :	1.94
	MA(100) :	3.28	MA(250) :	4.54
MACD	MACD :	-0.3	Signal :	-0.3
%K %D	K(14,3) :	23.6	D(3) :	23.8
RSI	RSI(14): 36.4
52-week	High :	7.92	Low :	1.53

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ SER ] has closed above bottom band by 28.6%. Bollinger Bands are 58.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	1.74 - 1.75	1.75 - 1.76
Low:	1.57 - 1.58	1.58 - 1.59
Close:	1.62 - 1.64	1.64 - 1.66

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.

Tue, 03 Mar 2026
Serina Therapeutics Advances SER-252 Parkinson’s Trial, Marking a Key Early Milestone for Investors - TipRanks

Tue, 24 Feb 2026
New drug SER-252 enters Phase 1b trial for advanced Parkinson's - Stock Titan

Tue, 24 Feb 2026
Serina Therapeutics Announces Dosing of First Patient in - GlobeNewswire

Thu, 19 Feb 2026
Serina Begins Phase 1b Registrational Trial Of SER-252 In Advanced Parkinson's - Nasdaq

Tue, 17 Feb 2026
Serina Therapeutics (SER) SVP awarded 69,000 stock options at $2.76 - Stock Titan

Tue, 17 Feb 2026
Director Simba Gill granted 92,000 Serina Therapeutics (SER) stock options - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: AMEX
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.